Prevalence of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Taiwanese patients with Type 2 diabetic mellitus

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1370-1374

  Chang, Yih Hsin ^a,b   Fu, Wen Mei ^c   Wu, Yu Hui ^d   Yeh, Chih Jung ^b   Huang, Chien Ning ^b,c   Shiau, Ming Yuh ^e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Lee General Hospital   (Taiwan)

^e HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Homocysteine; Methylenetetrahydrofolate reductase; Type 2 diabetes mellitus

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); GLUCOSE; LIPID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TAIWAN;

EID: 81555213544     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.09.020     Document Type: Article

References (37)

1. Doupis J., Eleftheriadou I., Kokkinos A., et al. Acute hyperhomocysteinemia impairs endothelium function in subjects with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010, 118:453-458.
2. Shimomura T., Anan F., Umeno Y., et al. Hyperhomocysteinaemia is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients. Eur J Neurol 2008, 15:289-294.
3. Aso Y., Yoshida N., Okumura K., et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004, 348:139-145.
4. Buysschaert M., Dramais A.S., Wallemacq P.E., et al. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000, 23:1816-1822.
5. Sun J., Xu Y., Zhu Y., et al. Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in type 2 diabetes mellitus. J Endocrinol Invest 2006, 29:814-820.
6. Mtiraoui N., Ezzidi I., Chaieb M., et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007, 75:99-106.
7. Ukinc K., Ersoz H.O., Karahan C., et al. Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009, 36:255-261.
8. Kalin A., Alatas O., Colak O. Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients. Eur J Endocrinol 2008, 158:47-52.
9. Sun J., Xu Y., Xue J., et al. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. Mol Cell Endocrinol 2005, 229:95-101.
10. Hoogeveen E.K., Kostense P.J., Jakobs C., et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101:1506-1511.
11. Sun J.Z., Xu Y., Lu H., et al. Polymorphism of the methylenetetrahydrofolate reductase gene association with homocysteine and ischemic stroke in type 2 diabetes. Neurol India 2009, 57:589-593.
12. Alam M.A., Husain S.A., Narang R., et al. Association of polymorphism in the thermolabile 5, 10-methylene tetrahydrofolate reductase gene and hyperhomocysteinemia with coronary artery disease. Mol Cell Biochem 2008, 310:111-117.
13. Engbersen A.M.T., Franken D.G., Boers G.H.J., et al. Thermolabile 5,10-Methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995, 56:142-150.
14. Harmon D.L., Woodside J.V., Yarnell J.W.G., et al. The Common "thermolabile" variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q J Med 1996, 89:571-577.
15. Friedman G., Goldschmidt N., Friedlander Y., et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentration. J Nutr 1999, 129:1656-1661.
16. Weisberg I., Tran P., Christensen B., et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172.
17. Ndrepepa G., Kastrati A., Braun S., et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2008, 18:66-73.
18. Miner S.E., Hegele R.A., Sparkes J., et al. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J 2000, 140:272-278.
19. Hodish I., Matetzky S., Selah B.A., et al. Effect of elevated homocysteine levels on clinical restenosis following percutaneous coronary intervention. Cardiology 2002, 97:214-217.
20. Födinger M., Hörl W.H., Sunder-Plassmann G. Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol 2000, 13:20-33.
21. Wilson P.W.F. Homocysteine and coronary heart disease: how great is the hazard?. JAMA 2002, 288:2042-2043.
22. Colwell J.A. Elevated plasma homocysteine and diabetic vascular disease. Diabetes Care 1997, 20:1805-1806.
23. Hoogeveen E.K., Kostense P.J., Beks P.J., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus. A population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133-138.
24. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995, 273(1995):1421-1428.
25. Araki A., Sako Y., Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993, 103:149-157.
26. Targher G., Bertolini L., Zenari L., et al. Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care 2000, 23:524-528.
27. Chico A., Pérez A., Córdoba A., et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?. Diabetologia 1998, 41:684-693.
28. Pavía C., Ferrer I., Valls C., et al. Total homocysteine in patients with type 1 diabetes. Diabetes Care 2000, 23:84-87.
29. Lanfredini M., Fiorina P., Peca M.G., et al. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Metabolism 1998, 47:915-921.
30. Vaccaro O., Perna A.F., Mancini F.P., et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000, 10:297-304.
31. Smulders Y.M., Rakic M., Slaats E.H., et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999, 22:125-132.
32. Fiorina P., Lanfredini M., Montanari A., et al. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am J Hypertens 1998, 11:1100-1117.
33. Maeda M., Yamamoto I., Fukuda M., et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diab Complicat 2008, 22:119-125.
34. Meigs J.B., Jacques P.F., Selhub J., et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 2001, 24:1403-1410.
35. Nakata Y., Katsuya T., Takami S., et al. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens 1998, 11:1019-1023.
36. Stehouwer C.D., Gall M.A., Hougaard P., et al. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 1999, 55:308-314.
37. Alfthan G., Pekkanen J., Jauhiainen M., et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994, 106:9-19.